Summary (tl;dr)

Reports indicate a potential executive order from President Trump to reclassify cannabis as a Schedule III drug in the U.S., a move that would significantly ease federal restrictions and has already caused cannabis company stocks, like Tilray, to surge.

Essential Background

Currently, cannabis is classified as a Schedule I substance under the U.S. Controlled Substances Act, a category reserved for drugs with no accepted medical use and a high potential for abuse, such as heroin and LSD. This classification imposes severe restrictions on medical research, prevents cannabis businesses from deducting ordinary business expenses under IRS Section 280E, and creates challenges for banking services. The Biden administration, through the Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA), initiated a review process, with HHS recommending in August 2023 that cannabis be moved to Schedule III, acknowledging its medical value and lower potential for abuse. The DEA then issued a proposed rule in May 2024 to implement this change.

The Full Story

As of December 2025, "schedule 3 drugs" and "Tilray stock" are trending due to recent reports suggesting that President Donald Trump is considering an executive order to direct federal agencies to reclassify marijuana from its current Schedule I status to Schedule III. This development follows a period of administrative review by the DEA, which began under the Biden administration after HHS recommended the change in August 2023 and the DEA issued a proposed rule in May 2024. The prospect of this reclassification, which would place cannabis alongside drugs like anabolic steroids and Tylenol with codeine, has caused a significant rally in cannabis stocks, with companies like Tilray Brands (TLRY) seeing their share prices jump by double digits. A White House official, however, has stated that no final decisions have yet been made.

Why It Matters

The reclassification to Schedule III, while not federally legalizing recreational cannabis, would mark the most significant federal policy shift for marijuana in decades. For the cannabis industry, it would primarily remove the burden of IRS Section 280E, allowing businesses to deduct standard operating expenses and potentially leading to higher profitability. This change would also facilitate medical research into cannabis and could make banking and financial services more accessible to cannabis-related businesses by reducing associated legal and regulatory risks. For investors, the anticipation of this regulatory shift has already generated considerable excitement, as evidenced by the surge in Tilray's stock, signaling a potential for increased growth and investment in the sector.

Geographic Location

• Washington, D.C., District of Columbia, United States (Discussions within the White House and federal agencies regarding cannabis reclassification, and potential executive order)
• United States (Nationwide impact of potential federal reclassification on cannabis industry and financial markets)